%0 Journal Article
%T Atezolizumab plus platinum-based regimen and bevacizumab: is it time to consider immunotherapy in a concurrent approach for lung cancer?
%A Andrea Bianco
%A Susan F. M. Campbell
%J SCIE-indexed Journal
%D 2019
%R 10.21037/25256
%X Targeting adaptive immunity is a game changer for cancer treatment, revolutionizing lung cancer management. Chemotherapy has been the standard treatment for lung cancer (1-4) until recently when molecular targets including genes harbouring cancer-driving mutations and immune check-points have emerged as targets for new therapies (5-12). With the increasing relevance of ICIs, clinical research is required to define which combination regimens provide the greatest benefits in lung cancer patients
%U http://tcr.amegroups.com/article/view/25256/html